AARD vs COAG
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease indications. COAG: Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for serious, rare blood coagulation disorders.
Side-by-side fundamentals
| Metric | AARD | COAG | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.48 | $49.23 | |
| Market cap as of 2026-07-23 | $128M | $2.3B | |
| PEG as of 2026-07-23 | -1.17 | n/a | |
| ROE as of 2026-07-23 | -61.7% | -34.8% | COAG higher |
| ROA as of 2026-07-23 | -56.3% | -32.8% | COAG higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 4.01 | -2.65 | |
| 1-year return as of 2026-07-22 close | -49.3% | +42.0% | COAG higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.